HomeAboutRankingsData Sources
ยฉ 2026 GeneE
๐Ÿงฌ
GeneE
10 sources retrieved ยท Most recent: April 2026 ยท Index updated 15 days ago
โ“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SCN10A
sodium voltage-gated channel alpha subunit 10
Chromosome 3 ยท 3p22.2
NCBI Gene: 6336Ensembl: ENSG00000185313.9HGNC: HGNC:10582UniProt: Q9Y5Y9
94PubMed Papers
21Diseases
78Drugs
2Pathogenic Variants
FUNCTIONAL ROLE
Ion ChannelTransporter
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
โœ“ Experimental GO Evidenceโœ“ Swiss-Prot Reviewed
regulation of monoatomic ion transmembrane transportregulation of atrial cardiac muscle cell membrane depolarizationextracellular exosomevoltage-gated sodium channel complexatrial fibrillationepisodic pain syndrome, familial, 2cardiac arrhythmiaepilepsy
โœฆAI Summary

SCN10A encodes Nav1.8, a tetrodotoxin-resistant voltage-gated sodium channel primarily expressed in peripheral nociceptive neurons 1. This channel plays critical roles in pain signaling and cardiac electrophysiology. In sensory neurons, Nav1.8 mediates neuropathic pain mechanisms and is essential for nociceptor function, with neurons expressing functional SCN10A-dependent sodium currents that respond to nociceptive stimuli 2. The channel also contributes to tissue healing by enabling nociceptor signaling through CGRP release, which modulates immune cell function during wound repair 3. In cardiac tissue, SCN10A variants contribute to conduction abnormalities, and therapeutic overexpression of its short isoform can rescue cardiac sodium current deficits and prevent arrhythmias 4. Mutations in SCN10A are associated with primary erythromelalgia, a rare pain disorder characterized by episodic burning pain in extremities 5. The gene is also implicated in small fiber neuropathy, where SCN10A variants expand the spectrum of genetic causes underlying this condition 6. Recent transcriptomic studies show sex-specific expression differences of SCN10A in spinal motor neurons, suggesting additional regulatory complexity 7. These findings establish SCN10A as a key player in pain processing, cardiac electrophysiology, and tissue repair mechanisms.

Sources cited
1
SCN10A encodes Nav1.8, a tetrodotoxin-resistant voltage-gated sodium channel selectively expressed in peripheral nociceptive neurons
PMID: 40010720
2
Neurons express functional SCN10A-dependent sodium currents and respond to nociceptive stimuli
PMID: 22750882
3
Nav1.8 nociceptors contribute to tissue healing through CGRP signaling that modulates immune cells
PMID: 38538784
4
SCN10A variants contribute to cardiac conduction abnormalities and therapeutic overexpression can prevent arrhythmias
PMID: 39973098
5
SCN10A mutations are associated with primary erythromelalgia pain disorder
PMID: 29299961
6
SCN10A variants are implicated in small fiber neuropathy
PMID: 39433284
7
SCN10A shows sex-specific expression differences in spinal motor neurons
PMID: 38289829
Disease Associationsโ“˜21
atrial fibrillationOpen Targets
0.71Strong
episodic pain syndrome, familial, 2Open Targets
0.71Strong
cardiac arrhythmiaOpen Targets
0.68Moderate
epilepsyOpen Targets
0.61Moderate
PainOpen Targets
0.61Moderate
bipolar disorderOpen Targets
0.60Moderate
SeizureOpen Targets
0.60Moderate
migraine disorderOpen Targets
0.60Moderate
major depressive disorderOpen Targets
0.60Moderate
partial epilepsyOpen Targets
0.60Moderate
PruritusOpen Targets
0.59Moderate
hemorrhoidOpen Targets
0.59Moderate
Ventricular arrhythmiaOpen Targets
0.58Moderate
amyotrophic lateral sclerosisOpen Targets
0.58Moderate
trigeminal neuralgiaOpen Targets
0.58Moderate
Back painOpen Targets
0.58Moderate
Lennox-Gastaut syndromeOpen Targets
0.57Moderate
alcohol dependenceOpen Targets
0.57Moderate
glossopharyngeal nerve disorderOpen Targets
0.57Moderate
premature ejaculationOpen Targets
0.56Moderate
Episodic pain syndrome, familial, 2UniProt
Pathogenic Variants2
NM_006514.4(SCN10A):c.2231T>A (p.Leu744Gln)Likely pathogenic
Episodic pain syndrome, familial, 2
โ˜…โ˜†โ˜†โ˜†2025โ†’ Residue 744
NM_006514.4(SCN10A):c.4201_4203del (p.Phe1401del)Likely pathogenic
Brugada syndrome
โ˜…โ˜†โ˜†โ˜†2017โ†’ Residue 1401
View on ClinVar โ†—
Drug Targets78
AFACIFENACINPhase II
Muscarinic acetylcholine receptor antagonist
overactive bladder
ARTICAINEApproved
Sodium channel alpha subunit blocker
ARTICAINE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
BENOXINATEApproved
Sodium channel alpha subunit blocker
Pruritus
BENOXINATE HYDROCHLORIDEPhase III
Sodium channel alpha subunit blocker
CARBAMAZEPINEApproved
Sodium channel alpha subunit blocker
epilepsy
CENOBAMATEApproved
Sodium channel alpha subunit inhibitor
Seizure
CHLOROPROCAINEApproved
Sodium channel alpha subunit blocker
CHLOROPROCAINE HYDROCHLORIDEPhase III
Sodium channel alpha subunit blocker
COCAINEApproved
Sodium channel alpha subunit blocker
COCAINE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
DIBUCAINEApproved
Sodium channel protein type V alpha subunit blocker
sunburn
DISOPYRAMIDEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
DISOPYRAMIDE PHOSPHATEApproved
Sodium channel alpha subunit blocker
Ventricular arrhythmia
DRONEDARONEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
DRONEDARONE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
atrial fibrillation
DSP-2230Phase I
Sodium channel protein type X alpha subunit blocker
neuropathic pain
DYCLONINEApproved
Sodium channel alpha subunit blocker
Pain
DYCLONINE HYDROCHLORIDEUNKNOWN
Sodium channel alpha subunit blocker
ENCAINIDEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
ENCAINIDE HYDROCHLORIDEUNKNOWN
Sodium channel alpha subunit blocker
ESLICARBAZEPINEApproved
Sodium channel alpha subunit blocker
epilepsy
ESLICARBAZEPINE ACETATEApproved
Sodium channel alpha subunit blocker
Seizure
ETHOTOINApproved
Sodium channel alpha subunit blocker
Seizure
ETIDOCAINEApproved
Sodium channel alpha subunit blocker
Pain
EVENAMIDEPhase III
Sodium channel alpha subunit blocker
treatment refractory schizophrenia
FOSPHENYTOINApproved
Sodium channel alpha subunit blocker
epilepsy
FOSPHENYTOIN SODIUMApproved
Sodium channel alpha subunit blocker
HEXYLCAINEApproved
Sodium channel alpha subunit blocker
INDECAINIDEApproved
Sodium channel alpha subunit blocker
IRAMPANELPhase I
Glutamate receptor ionotropic AMPA antagonist
LACOSAMIDEApproved
Sodium channel alpha subunit blocker
epilepsy
LAMOTRIGINEApproved
Sodium channel alpha subunit blocker
epilepsy
LIDOCAINEApproved
Sodium channel alpha subunit blocker
premature ejaculation
LIDOCAINE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
Pain
MEPHENYTOINApproved
Sodium channel alpha subunit blocker
epilepsy
MEPIVACAINEApproved
Sodium channel alpha subunit blocker
pain agnosia
MEPIVACAINE HYDROCHLORIDEPhase III
Sodium channel alpha subunit blocker
MEXILETINEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
MEXILETINE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
Ventricular arrhythmia
MORICIZINEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
NERISPIRDINEPhase II
Voltage-gated potassium channel blocker
multiple sclerosis
NKTR-171IND
Sodium channel alpha subunit blocker
neuropathic pain
ORPHENADRINEApproved
Glutamate [NMDA] receptor antagonist
Parkinson disease
ORPHENADRINE CITRATEApproved
Glutamate [NMDA] receptor antagonist
Pain
ORPHENADRINE HYDROCHLORIDEApproved
Histamine H1 receptor antagonist
Parkinson disease
OXCARBAZEPINEApproved
Sodium channel alpha subunit blocker
epilepsy
PF-04531083Phase II
Sodium channel protein type X alpha subunit blocker
Pain
PHENACEMIDEApproved
Sodium channel alpha subunit blocker
epilepsy
PHENAZOPYRIDINEApproved
Sodium channel alpha subunit blocker
Pain
PHENAZOPYRIDINE HYDROCHLORIDEPhase III
Sodium channel alpha subunit blocker
urinary tract infection
PHENYTOINApproved
Sodium channel alpha subunit blocker
epilepsy
PHENYTOIN SODIUMApproved
Sodium channel alpha subunit blocker
epilepsy
PRILOCAINEApproved
Sodium channel alpha subunit blocker
Pain
PRILOCAINE HYDROCHLORIDEUNKNOWN
Sodium channel alpha subunit blocker
PRIMIDONEApproved
GABA-A receptor; anion channel positive allosteric modulator
epilepsy
PROCAINAMIDEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
PROCAINAMIDE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
PROCAINEApproved
Sodium channel alpha subunit blocker
hemorrhoid
PROCAINE HYDROCHLORIDEPhase II
Sodium channel alpha subunit blocker
HIV infection
PROPAFENONEApproved
Beta-1 adrenergic receptor antagonist
cardiac arrhythmia
PROPAFENONE HYDROCHLORIDEApproved
Beta-1 adrenergic receptor antagonist
PROPARACAINEApproved
Sodium channel alpha subunit blocker
PROPARACAINE HYDROCHLORIDEUNKNOWN
Sodium channel alpha subunit blocker
PROPOXYCAINEApproved
Sodium channel alpha subunit blocker
Pain
QUINIDINEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
QUINIDINE GLUCONATEApproved
Sodium channel alpha subunit blocker
QUINIDINE SULFATEApproved
Sodium channel alpha subunit blocker
RALFINAMIDEPhase III
Glutamate [NMDA] receptor antagonist
neuropathic pain
RILUZOLEApproved
Sodium channel alpha subunit blocker
amyotrophic lateral sclerosis
ROPIVACAINEApproved
Sodium channel alpha subunit blocker
ROPIVACAINE HYDROCHLORIDEApproved
Sodium channel alpha subunit blocker
Pain
RUFINAMIDEApproved
Sodium channel alpha subunit blocker
TETRACAINEApproved
Sodium channel alpha subunit blocker
Pain
TETRACAINE HYDROCHLORIDEPhase III
Sodium channel alpha subunit blocker
TOCAINIDEApproved
Sodium channel alpha subunit blocker
cardiac arrhythmia
TOPIRAMATEApproved
Glutamate receptor ionotropic AMPA antagonist
epilepsy
ZONISAMIDEApproved
Sodium channel alpha subunit blocker
epilepsy
Related Genes
SCLT1Protein interaction89%SCN4BProtein interaction86%TRPM4Protein interaction86%CACNA2D1Protein interaction85%ANK3Protein interaction81%SCNN1AProtein interaction78%
Tissue Expression6 tissues
Heart
100%
Brain
7%
Ovary
0%
Bone Marrow
0%
Liver
0%
Lung
0%
Gene Interaction Network
Click a node to explore
SCN10ASCLT1SCN4BTRPM4CACNA2D1ANK3SCNN1A
PROTEIN STRUCTURE
Preparing viewerโ€ฆ
PDB7WE4 ยท 2.70 ร… ยท EM
View on RCSB โ†—
Constraintโ“˜
LOEUFโ“˜
1.06LoF Tolerant
pLIโ“˜
0.00Tolerant
Observed/Expected LoF0.93 [0.81โ€“1.06]
RankingsWhere SCN10A stands among ~20K protein-coding genes
  • #5,104of 20,598
    Most Researched94 ยท top quartile
  • #12of 1,025
    FDA-Approved Drug Targets60 ยท top 5%
  • #4,334of 5,498
    Most Pathogenic Variants2
  • #10,623of 17,882
    Most Constrained (LOEUF)1.06
Genes detectedSCN10A
Sources retrieved10 papers
Response timeโ€”
๐Ÿ“„ Sources
10โ–ผ
1
CGRP sensory neurons promote tissue healing via neutrophils and macrophages.
PMID: 38538784
Nature ยท 2024
1.00
2
SCN10A-short gene therapy to restore conduction and protect against malignant cardiac arrhythmias.
PMID: 39973098
Eur Heart J ยท 2025
0.90
3
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis ยท 2022
0.80
4
Erythromelalgia.
PMID: 29299961
Vasa ยท 2018
0.70
5
The Evolving Landscape of Small Fiber Neuropathy.
PMID: 39433284
Semin Neurol ยท 2025
0.60